Seagen (SGEN) stock roared 17% higher on Merck’s (MRK) buyout plan

June 17, 2022 07:37 PM BST | By Versha Jain
 Seagen (SGEN) stock roared 17% higher on Merck’s (MRK) buyout plan
Image source: © Transversospinales | Megapixl.com
Highlights:
  • Washington-based Seagen Inc. (NASDAQ:SGEN) stock rose 16.76% on Friday.
  • Merck & Company, Inc. (MRK) is considering buying the biotech firm. 
  • However, their talks are not yet conclusive.

Washington-based Seagen Inc. (NASDAQ:SGEN) stock rose 16.76% to US$171.385 at 12:14 pm ET on Friday after WSJ reported that Merck & Company, Inc. (MRK) is considering buying the cancer-focused biotechnology firm

According to the report, a possible deal could be still far away, although talks are going on; and they may also settle for a marketing collaboration. Seagen currently has a market capitalization of US$31.50 billion, while Merck’s market value is around US$212 billion.

After the news, the MRK stock plunged 1.50% to US$83.62 at 12:32 pm ET. If the deal gets finalized, Merck will boast an impressive lineup of cancer drugs.

Also Read: CELU to CMPI: Explore top 5 biotech stocks with over 100% YTD return

Both the companies have already been collaborating on breast-cancer treatment. They plan to test Merck’s top-selling product Keytruda in combination with another drug in an experiment.

Merck has reportedly offered Seagen US$600 million up-front out of its total five million shares worth US$1 billion for the takeover.

The healthcare sector saw fewer deals this year amid a topsy-turvy market condition. The industry typically sees a lot of deal-making each year. The fewer deals in 2022 compared to last year were due to the high valuations and increased risks of antitrust scrutiny.

Also Read: HST to VTR: Should you explore these 5 REITs as inflation shoots up?

Seagen, formerly Seattle Genetics, develops therapies to treat cancers. Its treatments use the monoclonal antibodies’ targeting ability to produce cancer cell-killing agents. 

Seagen’s lead product Adcetris has received six “indications approval” for treating Hodgkin lymphoma and T-cell lymphoma. It also licenses its antibody-drug conjugate technology to other leading pharmaceutical companies.

Also Read: Top agri stocks to watch amid rising prices: ADM, CTVA, MOS, BG & CF

Seagen (SGEN) stock roared 17% higher on Merck’s (MRK) buyout plan

Also Read: Five financial stocks to watch in Q3: FHN, Y, WRB, LPLA & PGR

Financials:

Seagen brought its IPO in 2001. In the quarter ended March 31, 2022, it generated a revenue of US$426.4 million compared to US$331.98 million in the same quarter a year ago. The net loss was US$136.5 million versus a net loss of US$121.4 million in the previous year. 

Also Read: Top healthcare stocks to explore in June: JNJ, LLY, ABBV, MRK & BMY

Seagen had US$261 million in cash and cash equivalents as of March 31, 2022.

Its stock traded in the range of US$192.79 to US$105.43 in the last 52 weeks.

Also Read: GOGO to LPTV: Five communication stocks to watch in July

Bottom line:

According to analysts, Merck needs more pipeline products to bolster its portfolio. Merck CEO Robert Davis, they say, is looking for more do more deals. The S&P 500’s biotechnology Index fell around 7% YTD; RGEN stock dropped 5.7% YTD at the closing price of June 16.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next